Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|March 20, 2025

Other Investigational Drug Delivery Systems in NMIBC

Author(s)Chad A. Reichard, MD , Karim Chamie, MD, MSHS , R. Jonathan Henderson, MD

Experts briefly discuss investigational mitomycin delivery systems UGN-102 and UGN-103, which are being evaluated in intermediate-risk non–muscle-invasive bladder cancer (NMIBC), and share their impressions of the safety and efficacy results from the ENVISION phase 3 trial for UGN-102.

Episodes in this series

EP. 1 Standard of Care and Intravesical Chemotherapy in NMIBC

EP. 1 Standard of Care and Intravesical Chemotherapy in NMIBC

EP. 2 BCG for treatment of NMIBC

EP. 2 BCG for treatment of NMIBC

EP. 3 Cystectomy in NMIBC

EP. 3 Cystectomy in NMIBC

EP. 4 New Intravesical Delivery Systems and TAR-200 in NMIBC

EP. 4 New Intravesical Delivery Systems and TAR-200 in NMIBC

EP. 5 TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP. 5 TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP. 6 TAR-200 Clinical Development Program in NMIBC

EP. 6 TAR-200 Clinical Development Program in NMIBC

EP. 7 Other Investigational Drug Delivery Systems in NMIBC

EP. 7 Other Investigational Drug Delivery Systems in NMIBC

EP. 8 Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP. 8 Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP. 9 FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP. 9 FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP. 10 Use and Sequencing of Novel Treatments in NMIBC

EP. 10 Use and Sequencing of Novel Treatments in NMIBC

EP. 11 Communication of Treatment Options for High-Risk NMIBC

EP. 11 Communication of Treatment Options for High-Risk NMIBC

EP. 12 Checkpoint Inhibitors for Treatment of NMIBC

EP. 12 Checkpoint Inhibitors for Treatment of NMIBC

EP. 13 Unmet Needs in NMIBC

EP. 13 Unmet Needs in NMIBC

EP. 14 Operationalizing TAR-200 and Other Delivery Systems in Practice

EP. 14 Operationalizing TAR-200 and Other Delivery Systems in Practice

EP. 15 Patient Communication and Treatment Adherence in NMIBC

EP. 15 Patient Communication and Treatment Adherence in NMIBC

EP. 16 Uptake of New Treatments in Urology Practice

EP. 16 Uptake of New Treatments in Urology Practice

EP. 17 Final Thoughts and Clinical Trials in NMIBC

EP. 17 Final Thoughts and Clinical Trials in NMIBC

Video content above is prompted by the following:

Please briefly discuss investigational mitomycin delivery systems UGN-102 and UGN-103, which are being evaluated in intermediate-risk NMIBC. What are your impressions of the safety and efficacy results from the ENVISION phase 3 trial for UGN-102?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Surabhi Amar, MD, MHA, MBBS; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures

Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC

Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study

Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer

BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC

© 2025 MJH Life Sciences^®

All rights reserved.